Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

William Tillett; Alexander Allen; Laura Tucker; David Chandler; Coziana Ciurtin; Charlotte Davis; Andrew Dick; Amy Foulkes; Nicola Gullick; Philip Helliwell; Deepak Jadon; Gareth Jones; Stuart Kyle; Vishnu Madhok; Neil McHugh; Andrew Parkinson; Tim Raine; Stefan Siebert; Catherine Smith; Laura C Coates

doi:10.1093/rheumatology/keaa526

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Rheumatology (Oxford). 2021 Apr 6;60(4):1588-1592. doi: 10.1093/rheumatology/keaa526.

Authors

William Tillett¹, Alexander Allen², Laura Tucker³, David Chandler⁴, Coziana Ciurtin⁵, Charlotte Davis⁶, Andrew Dick⁷, Amy Foulkes⁸, Nicola Gullick⁹, Philip Helliwell¹⁰, Deepak Jadon¹¹, Gareth Jones¹², Stuart Kyle¹³, Vishnu Madhok¹⁴, Neil McHugh¹⁵, Andrew Parkinson¹⁶, Tim Raine¹⁷, Stefan Siebert¹⁸, Catherine Smith¹⁹, Laura C Coates²⁰

Affiliations

¹ Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK.
² Clinical Affairs, British Society for Rheumatology, London, UK.
³ Department of Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
⁴ Psoriasis And Psoriatic Arthritis Alliance (PAPAA), St Albans, Hertfordshire, UK.
⁵ Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
⁶ Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁷ University of Bristol, Cellular and Molecular Medicine, Bristol Eye Hospital, Bristol, UK.
⁸ University of Manchester, Institute of Inflammation and Repair, Manchester, UK.
⁹ Guy's and St Thomas' NHS Foundation Trust, Rheumatology, London, UK.
¹⁰ University of Leeds, Section of Musculoskeletal Disease, Leeds, UK.
¹¹ Cambridge University Hospitals NHS Foundation Trust, Rheumatology, Cambridge, UK.
¹² Epidemiology Group, Institute of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen, UK.
¹³ North Devon District Hospital Rheumatology, Barnstaple, UK.
¹⁴ Park House Surgery, Bagshot, Surrey, UK.
¹⁵ Royal National Hospital for Rheumatic Diseases, Bath, UK.
¹⁶ Patient Partner, UK.
¹⁷ Gastroenterology, Addenbrooke's Hospital, Cambridge, UK.
¹⁸ Rheumatology, Institute of Infection, Immunity and Inflammation, Glasgow, UK.
¹⁹ Dermatology, Guy's and St Thomas' Hospital, London, UK.
²⁰ Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK.

PMID: 33097948
DOI: 10.1093/rheumatology/keaa526

Abstract

The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.

Keywords: bDMARDs targeted; psoriatic_arthritis treatment biologics; tsDMARDs guideline management.

Publication types

Practice Guideline

MeSH terms

Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Biological Products / therapeutic use*
Humans
Rheumatology / standards
Treatment Outcome

Substances

Antirheumatic Agents
Biological Products

Abstract

Publication types

MeSH terms

Substances

Grants and funding